首页 > 最新文献

Biomedical and environmental sciences : BES最新文献

英文 中文
Elimination Progress of Human Rabies in Beijing, 1973-2023: A Descriptive Epidemiological Study. 1973-2023年北京市人类狂犬病消灭进展:描述性流行病学研究。
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.169
Tao Zhou, Xiaomei Li, Cheng Gong, Ming Luo, Dan Zhao, Jingbin Pan, Ziang Li, Quanyi Wang, Luodan Suo, Li Lu
{"title":"Elimination Progress of Human Rabies in Beijing, 1973-2023: A Descriptive Epidemiological Study.","authors":"Tao Zhou, Xiaomei Li, Cheng Gong, Ming Luo, Dan Zhao, Jingbin Pan, Ziang Li, Quanyi Wang, Luodan Suo, Li Lu","doi":"10.3967/bes2024.169","DOIUrl":"https://doi.org/10.3967/bes2024.169","url":null,"abstract":"","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1338-1342"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Willingness to Pay for Antiretroviral Drugs Covered by Medical Insurance among People Living with HIV in 18 Chinese Cities. 中国18个城市艾滋病病毒感染者医疗保险抗逆转录病毒药物支付意愿调查
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.105
Jingkun Hu, Houlin Tang, Wenting Kang, Shuyu Wang, Jie Xu, Decai Zhao, Yang Hao, Xinlun Wang, Fan Lyu, Guang Zhang, Peng Xu

Objective: Antiretroviral drugs covered by medical insurance have been gradually used by people living with human immunodeficiency virus (PLWH) in recent years in China. This study aimed to analyze their willingness to pay (WTP) for antiretroviral drugs.

Methods: A mixed-methods study design involving a cross-sectional survey and in-depth interviews was conducted. A cross-sectional survey was performed to collect data on the general characteristics, economic status, antiretroviral therapy (ART) status, and WTP of PLWH in 18 Chinese cities from August 2022 to February 2023. Multivariate logistic regression was used to analyze the factors associated with WTP. Representatives of PLWH were interviewed via in-depth interviews, and the data were thematically analyzed.

Results: Among the 941 PLWH, 271 (28.80%) were willing to pay for antiretroviral drugs covered by medical insurance. For basic medical insurance for urban and rural residents, PLWH with the following characteristics were more willing to pay: an educational level of senior high school or technical secondary school, having an undergraduate degree or higher, frequently working away from their hometowns, and homosexual transmission. Off-farm workers and recipients of government medical aid were more unwilling to pay. For basic medical insurance for urban employees, PLWH with the following characteristics were more willing to pay: frequently working away from their hometowns; homosexual transmission; personal annual income ≥ 100,000 CNY; and adverse events of antiretroviral drugs. The main reasons for PLWH's WTP for antiretroviral drugs covered by medical insurance were that the drugs had fewer adverse events and were easier to administer. The main reasons for PLWH's unwillingness to pay were financial difficulties and privacy concerns.

Conclusion: Nearly one-third of PLWH are willing to pay for antiretroviral drugs covered by medical insurance. In the future, PLWH with a high WTP can be guided to use these drugs.

目的:近年来,抗逆转录病毒药物在医疗保险范围内逐渐被人类免疫缺陷病毒(PLWH)感染者使用。本研究旨在分析他们对抗逆转录病毒药物的支付意愿(WTP)。方法:采用横断面调查和深度访谈相结合的混合方法研究设计。通过横断面调查,收集了2022年8月至2023年2月中国18个城市PLWH的一般特征、经济状况、抗逆转录病毒治疗(ART)状况和WTP数据。采用多因素logistic回归分析WTP的相关因素。通过深度访谈对PLWH的代表进行访谈,并对数据进行主题分析。结果:941名艾滋病毒感染者中,271人(28.80%)愿意支付医疗保险覆盖的抗逆转录病毒药物。对于城乡居民基本医疗保险,具有高中或中专学历、本科及以上学历、经常外出工作、同性传播等特征的人群支付意愿更高。非农业工人和接受政府医疗救助的人更不愿意付钱。对于城镇职工基本医疗保险,具有以下特征的农民工更愿意支付:经常远离家乡工作;同性恋传播;个人年收入≥10万元;以及抗逆转录病毒药物的不良反应。PLWH将抗逆转录病毒药物纳入医疗保险的主要原因是这些药物的不良事件较少,而且更容易管理。PLWH不愿支付的主要原因是经济困难和隐私问题。结论:近三分之一的艾滋病病毒感染者愿意支付医疗保险覆盖的抗逆转录病毒药物。在未来,高WTP的PLWH可以被引导使用这些药物。
{"title":"Willingness to Pay for Antiretroviral Drugs Covered by Medical Insurance among People Living with HIV in 18 Chinese Cities.","authors":"Jingkun Hu, Houlin Tang, Wenting Kang, Shuyu Wang, Jie Xu, Decai Zhao, Yang Hao, Xinlun Wang, Fan Lyu, Guang Zhang, Peng Xu","doi":"10.3967/bes2024.105","DOIUrl":"https://doi.org/10.3967/bes2024.105","url":null,"abstract":"<p><strong>Objective: </strong>Antiretroviral drugs covered by medical insurance have been gradually used by people living with human immunodeficiency virus (PLWH) in recent years in China. This study aimed to analyze their willingness to pay (WTP) for antiretroviral drugs.</p><p><strong>Methods: </strong>A mixed-methods study design involving a cross-sectional survey and in-depth interviews was conducted. A cross-sectional survey was performed to collect data on the general characteristics, economic status, antiretroviral therapy (ART) status, and WTP of PLWH in 18 Chinese cities from August 2022 to February 2023. Multivariate logistic regression was used to analyze the factors associated with WTP. Representatives of PLWH were interviewed <i>via</i> in-depth interviews, and the data were thematically analyzed.</p><p><strong>Results: </strong>Among the 941 PLWH, 271 (28.80%) were willing to pay for antiretroviral drugs covered by medical insurance. For basic medical insurance for urban and rural residents, PLWH with the following characteristics were more willing to pay: an educational level of senior high school or technical secondary school, having an undergraduate degree or higher, frequently working away from their hometowns, and homosexual transmission. Off-farm workers and recipients of government medical aid were more unwilling to pay. For basic medical insurance for urban employees, PLWH with the following characteristics were more willing to pay: frequently working away from their hometowns; homosexual transmission; personal annual income ≥ 100,000 CNY; and adverse events of antiretroviral drugs. The main reasons for PLWH's WTP for antiretroviral drugs covered by medical insurance were that the drugs had fewer adverse events and were easier to administer. The main reasons for PLWH's unwillingness to pay were financial difficulties and privacy concerns.</p><p><strong>Conclusion: </strong>Nearly one-third of PLWH are willing to pay for antiretroviral drugs covered by medical insurance. In the future, PLWH with a high WTP can be guided to use these drugs.</p>","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1283-1293"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological Characteristics of Measles-Mumps-Rubella in China's Mainland during 2014-2021. 2014-2021 年中国内地麻疹-腮腺炎-风疹流行病学特征。
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.135
Zhuowei Li, Lele Deng, Jiandong Li, Xiang Ren, Guangxue He

Objective: To analyze the epidemiological characteristics of measles, mumps, and rubella (MMR) between 2014 and 2021 and identify potential strategies and measures for the prevention and control of MMR in China.

Methods: Data on MMR was obtained from China's National Notifiable Disease Reporting System for the period from 2014 to 2021. Spatiotemporal distributions were analyzed using SaTScan; temporal trends were analyzed using JoinPoint; and clusters were visualized using ArcGIS.

Results: A total of 1,808,067 cases of MMR were reported from 2014 to 2021 in China's mainland, most of which were children and students under the age of 20. The incidence of measles declined during 2014-2021, whereas that of mumps and rubella peaked in 2019. MMR-reported cases generally peaked from March to July; however, high numbers of mumps cases were reported from September to November in 2020-2021. Measles and rubella clusters predominantly occurred in Western China, whereas clusters of mumps were generally found in the southern region.

Conclusion: The relatively heterogeneous epidemiological characteristics of MMR have highlighted the weaknesses and gaps in surveillance and timely control of MMR transmission in China's mainland. Real-time and intelligent monitoring data should be collected for evidence-based early interventions.

目的:分析2014 - 2021年中国麻疹、腮腺炎和风疹(MMR)流行病学特征,探讨预防和控制MMR的潜在策略和措施。方法:2014 - 2021年的MMR数据来自中国国家法定疾病报告系统。利用SaTScan分析其时空分布;使用JoinPoint分析时间趋势;并利用ArcGIS对聚类进行可视化。结果:2014 - 2021年,中国大陆共报告MMR病例1,808,067例,其中以20岁以下儿童和学生为主。2014-2021年期间,麻疹发病率下降,而腮腺炎和风疹发病率在2019年达到峰值。mmr报告病例一般在3月至7月达到高峰;然而,在2020-2021年9月至11月期间报告了大量腮腺炎病例。麻疹和风疹聚集性病例主要发生在中国西部地区,而流行性腮腺炎聚集性病例一般发生在南方地区。结论:MMR的流行病学特征相对异质性突出了中国大陆地区在监测和及时控制MMR传播方面的薄弱环节和差距。应收集实时和智能监测数据,以便进行循证早期干预。
{"title":"Epidemiological Characteristics of Measles-Mumps-Rubella in China's Mainland during 2014-2021.","authors":"Zhuowei Li, Lele Deng, Jiandong Li, Xiang Ren, Guangxue He","doi":"10.3967/bes2024.135","DOIUrl":"https://doi.org/10.3967/bes2024.135","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the epidemiological characteristics of measles, mumps, and rubella (MMR) between 2014 and 2021 and identify potential strategies and measures for the prevention and control of MMR in China.</p><p><strong>Methods: </strong>Data on MMR was obtained from China's National Notifiable Disease Reporting System for the period from 2014 to 2021. Spatiotemporal distributions were analyzed using SaTScan; temporal trends were analyzed using JoinPoint; and clusters were visualized using ArcGIS.</p><p><strong>Results: </strong>A total of 1,808,067 cases of MMR were reported from 2014 to 2021 in China's mainland, most of which were children and students under the age of 20. The incidence of measles declined during 2014-2021, whereas that of mumps and rubella peaked in 2019. MMR-reported cases generally peaked from March to July; however, high numbers of mumps cases were reported from September to November in 2020-2021. Measles and rubella clusters predominantly occurred in Western China, whereas clusters of mumps were generally found in the southern region.</p><p><strong>Conclusion: </strong>The relatively heterogeneous epidemiological characteristics of MMR have highlighted the weaknesses and gaps in surveillance and timely control of MMR transmission in China's mainland. Real-time and intelligent monitoring data should be collected for evidence-based early interventions.</p>","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1273-1282"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Need of Practical Strategy for Improving Awareness of Acceptance of Tuberculosis Preventive Treatment among the Public and the Healthcare Workers. 提高公众和医护人员对结核病预防治疗接受程度的实用战略的必要性。
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.174
Xiaoping Dong
{"title":"Need of Practical Strategy for Improving Awareness of Acceptance of Tuberculosis Preventive Treatment among the Public and the Healthcare Workers.","authors":"Xiaoping Dong","doi":"10.3967/bes2024.174","DOIUrl":"https://doi.org/10.3967/bes2024.174","url":null,"abstract":"","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1233-1234"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
bla NDM-1 Carried by a Transferable Plasmid in a Salmonella Strain Isolated from Healthy Individuals. 从健康个体分离的沙门氏菌菌株的可转移质粒携带bla NDM-1。
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.104
Wei Zeng, Ming Luo, Pengcheng Du, Zhenpeng Li, Yao Peng, Mengyu Wang, Wenxuan Zhao, Huayao Zhang, Yang Li, Pengjie Luo, Yannong Wu, Jialiang Xu, Xu Li, Xin Lu, Biao Kan

Objective: Our study aimed to conduct genomic characterization of Salmonella strains carrying the bla NDM-1 gene in the intestinal tract of healthy individuals. The objectives were to underscore the importance of genomic surveillance for drug resistance in both commensal and pathogenic bacteria among healthy populations, and to establish protocols for regulating drug resistance plasmids based on the completion of a comprehensive map of drug resistance plasmid genomes.

Methods: We performed antimicrobial susceptibility testing and employed second- and third-generation sequencing techniques to analyze Salmonella strains harboring the bla NDM-1 gene, to surveil drug-resistant bacteria in the intestines of healthy subjects. Sequence comparison was conducted using both core- and pan-genome approaches. Concurrently, conjugation experiments were carried out to assess the efficiency of plasmid transfer.

Results: We isolated a carbapenem-resistant Salmonella enterica serovar Typhimurium strain from a healthy food worker in China. This strain harbored an IncHI2/IncHI2A plasmid carrying bla NDM-1 along with multiple antibiotic resistance genes (ARGs). Our findings highlight the potential for asymptomatic carriers to facilitate the transmission of ARGs. Pan-genomic analysis revealed that bla NDM-1-positive plasmids could traverse bacterial species barriers, facilitating cross-host transmission.

Conclusion: This study marks the first detection of bla NDM-1 in Salmonella strains isolated from healthy individuals. We underscore the risk associated with the transmission of conjugative hybrid plasmids carrying bla NDM-1, which have the potential to be harbored and transmitted among healthy individuals. Enhanced surveillance of drug-resistant pathogens and plasmids in the intestinal microbiota of healthy individuals could provide insights into the risk of ARG transmission and pathways for population-wide dissemination via ARG transfer factors.

目的:对健康人肠道携带bla NDM-1基因的沙门氏菌进行基因组鉴定。其目的是强调对健康人群中共生菌和致病菌的耐药性进行基因组监测的重要性,并在完成耐药性质粒基因组综合图谱的基础上,制定耐药性质粒调控方案。方法:采用药敏试验和第二代和第三代测序技术对携带bla NDM-1基因的沙门氏菌进行分析,监测健康受试者肠道内的耐药菌。序列比较采用核心基因组和泛基因组两种方法。同时,进行了偶联实验来评估质粒转移的效率。结果:我们从中国一名健康食品工作者身上分离到一株耐碳青霉烯的肠沙门氏菌血清型鼠伤寒杆菌。该菌株携带携带bla NDM-1和多种抗生素耐药基因(ARGs)的IncHI2/IncHI2A质粒。我们的发现强调了无症状携带者促进ARGs传播的可能性。泛基因组分析显示,bla ndm -1阳性质粒可以跨越细菌物种屏障,促进跨宿主传播。结论:本研究首次在健康个体分离的沙门氏菌中检出bla NDM-1。我们强调与携带bla NDM-1的共轭杂交质粒传播相关的风险,这种质粒有可能在健康个体中被携带和传播。加强对健康个体肠道微生物群中耐药病原体和质粒的监测,可以深入了解ARG传播的风险以及通过ARG转移因子在人群中传播的途径。
{"title":"<i>bla</i> <sub>NDM-1</sub> Carried by a Transferable Plasmid in a <i>Salmonella</i> Strain Isolated from Healthy Individuals.","authors":"Wei Zeng, Ming Luo, Pengcheng Du, Zhenpeng Li, Yao Peng, Mengyu Wang, Wenxuan Zhao, Huayao Zhang, Yang Li, Pengjie Luo, Yannong Wu, Jialiang Xu, Xu Li, Xin Lu, Biao Kan","doi":"10.3967/bes2024.104","DOIUrl":"https://doi.org/10.3967/bes2024.104","url":null,"abstract":"<p><strong>Objective: </strong>Our study aimed to conduct genomic characterization of <i>Salmonella</i> strains carrying the <i>bla</i> <sub>NDM-1</sub> gene in the intestinal tract of healthy individuals. The objectives were to underscore the importance of genomic surveillance for drug resistance in both commensal and pathogenic bacteria among healthy populations, and to establish protocols for regulating drug resistance plasmids based on the completion of a comprehensive map of drug resistance plasmid genomes.</p><p><strong>Methods: </strong>We performed antimicrobial susceptibility testing and employed second- and third-generation sequencing techniques to analyze <i>Salmonella</i> strains harboring the <i>bla</i> <sub>NDM-1</sub> gene, to surveil drug-resistant bacteria in the intestines of healthy subjects. Sequence comparison was conducted using both core- and pan-genome approaches. Concurrently, conjugation experiments were carried out to assess the efficiency of plasmid transfer.</p><p><strong>Results: </strong>We isolated a carbapenem-resistant <i>Salmonella</i> enterica serovar Typhimurium strain from a healthy food worker in China. This strain harbored an IncHI2/IncHI2A plasmid carrying <i>bla</i> <sub>NDM-1</sub> along with multiple antibiotic resistance genes (ARGs). Our findings highlight the potential for asymptomatic carriers to facilitate the transmission of ARGs. Pan-genomic analysis revealed that <i>bla</i> <sub>NDM-1</sub>-positive plasmids could traverse bacterial species barriers, facilitating cross-host transmission.</p><p><strong>Conclusion: </strong>This study marks the first detection of <i>bla</i> <sub>NDM-1</sub> in <i>Salmonella</i> strains isolated from healthy individuals. We underscore the risk associated with the transmission of conjugative hybrid plasmids carrying <i>bla</i> <sub>NDM-1</sub>, which have the potential to be harbored and transmitted among healthy individuals. Enhanced surveillance of drug-resistant pathogens and plasmids in the intestinal microbiota of healthy individuals could provide insights into the risk of ARG transmission and pathways for population-wide dissemination <i>via</i> ARG transfer factors.</p>","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1252-1261"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Strategies for Tuberculosis: Progress and Lessons Learned. 结核病的治疗策略:进展和经验教训。
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.168
Qingfeng Sun, Shanshan Li, Mengqiu Gao, Yu Pang

Tuberculosis (TB) remains a significant global health challenge, ranking second only to COVID-19 as the leading cause of death from a single infectious agent, with 1.3 million TB-related deaths reported in 2022. Treatment efficacy has been compromised by the emergence of drug-resistant strains, including rifampin-resistant TB (RR-TB), multidrug-resistant TB (MDR-TB), and extensively drug-resistant TB (XDR-TB). Although first-line drugs like isoniazid, rifampicin, pyrazinamide, and ethambutol form the cornerstone of TB therapy, the rise of resistant strains necessitates the use of second-line drugs, which often come with increased toxicity and limited accessibility. Recent advances have focused on repurposing existing compounds and developing new drugs with novel mechanisms of action. Promising agents such as second-generation bedaquiline analogs (TBAJ-587, TBAJ-876), sudapyridine (WX-081), delamanid, pretomanid, and TBI-166 (pyrifazimine) have shown efficacy against resistant Mtb strains. Innovative treatment regimens like the BPaLM protocol-combining bedaquiline, pretomanid, linezolid, and moxifloxacin-offer shorter, all-oral therapies with higher cure rates. Personalized treatment durations and dose optimizations are becoming feasible through risk stratification algorithms and pharmacokinetic/pharmacodynamic studies. Immunotherapy is emerging as a complementary strategy to enhance the host's immune response against Mtb. Agents such as vitamin D, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), statins, metformin, and biological agents like interleukins and granulocyte-macrophage colony-stimulating factor are under exploration. Additionally, cell therapies involving mesenchymal stem cells and immune effector cells present new therapeutic avenues. Despite these advancements, significant challenges remain in achieving the World Health Organization's "End TB Strategy" goals, particularly as the COVID-19 pandemic has diverted resources and attention. Ongoing research and global collaboration are crucial to develop novel therapeutic strategies, optimize treatment regimens, and ultimately reduce the global burden of TB.

结核病仍然是一项重大的全球卫生挑战,是仅次于COVID-19的第二大单一传染性病原体死亡原因,2022年报告的结核病相关死亡人数为130万。由于出现耐药菌株,包括耐利福平结核病(RR-TB)、耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB),治疗效果受到影响。虽然异烟肼、利福平、吡嗪酰胺和乙胺丁醇等一线药物是结核病治疗的基石,但耐药菌株的增加需要使用二线药物,这些药物往往毒性更大,可及性也有限。最近的进展集中在重新利用现有化合物和开发具有新的作用机制的新药。有前景的药物如第二代贝达喹啉类似物(TBAJ-587、TBAJ-876)、苏达吡啶(WX-081)、delamanid、pretomanid和TBI-166 (pyrifazimine)已显示出对耐药结核杆菌菌株的疗效。创新的治疗方案,如BPaLM方案——联合贝达喹啉、普雷托马奈、利奈唑胺和莫西沙星——提供了更短的全口服治疗,治愈率更高。通过风险分层算法和药代动力学/药效学研究,个性化治疗持续时间和剂量优化变得可行。免疫疗法正在成为增强宿主对结核分枝杆菌免疫反应的一种补充策略。诸如维生素D、皮质类固醇、非甾体抗炎药(NSAIDs)、他汀类药物、二甲双胍以及白细胞介素和粒细胞-巨噬细胞集落刺激因子等生物制剂正在探索中。此外,涉及间充质干细胞和免疫效应细胞的细胞疗法提供了新的治疗途径。尽管取得了这些进展,但在实现世界卫生组织“终止结核病战略”目标方面仍存在重大挑战,特别是在COVID-19大流行转移了资源和注意力的情况下。正在进行的研究和全球合作对于制定新的治疗策略、优化治疗方案以及最终减轻结核病的全球负担至关重要。
{"title":"Therapeutic Strategies for Tuberculosis: Progress and Lessons Learned.","authors":"Qingfeng Sun, Shanshan Li, Mengqiu Gao, Yu Pang","doi":"10.3967/bes2024.168","DOIUrl":"10.3967/bes2024.168","url":null,"abstract":"<p><p>Tuberculosis (TB) remains a significant global health challenge, ranking second only to COVID-19 as the leading cause of death from a single infectious agent, with 1.3 million TB-related deaths reported in 2022. Treatment efficacy has been compromised by the emergence of drug-resistant strains, including rifampin-resistant TB (RR-TB), multidrug-resistant TB (MDR-TB), and extensively drug-resistant TB (XDR-TB). Although first-line drugs like isoniazid, rifampicin, pyrazinamide, and ethambutol form the cornerstone of TB therapy, the rise of resistant strains necessitates the use of second-line drugs, which often come with increased toxicity and limited accessibility. Recent advances have focused on repurposing existing compounds and developing new drugs with novel mechanisms of action. Promising agents such as second-generation bedaquiline analogs (TBAJ-587, TBAJ-876), sudapyridine (WX-081), delamanid, pretomanid, and TBI-166 (pyrifazimine) have shown efficacy against resistant Mtb strains. Innovative treatment regimens like the BPaLM protocol-combining bedaquiline, pretomanid, linezolid, and moxifloxacin-offer shorter, all-oral therapies with higher cure rates. Personalized treatment durations and dose optimizations are becoming feasible through risk stratification algorithms and pharmacokinetic/pharmacodynamic studies. Immunotherapy is emerging as a complementary strategy to enhance the host's immune response against Mtb. Agents such as vitamin D, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), statins, metformin, and biological agents like interleukins and granulocyte-macrophage colony-stimulating factor are under exploration. Additionally, cell therapies involving mesenchymal stem cells and immune effector cells present new therapeutic avenues. Despite these advancements, significant challenges remain in achieving the World Health Organization's \"End TB Strategy\" goals, particularly as the COVID-19 pandemic has diverted resources and attention. Ongoing research and global collaboration are crucial to develop novel therapeutic strategies, optimize treatment regimens, and ultimately reduce the global burden of TB.</p>","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1310-1323"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indoor Radon Survey in 31 Provincial Capital Cities and Estimation of Lung Cancer Risk in Urban Areas of China. 中国31个省会城市室内氡调查及城市地区肺癌风险评估
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.165
Xiaoxiang Miao, Yinping Su, Changsong Hou, Yanchao Song, Bowei Ding, Hongxing Cui, Yunyun Wu, Quanfu Sun

Objective: We aimed to analyze the current indoor radon level and estimate the population risk of radon-induced lung cancer in urban areas of China.

Methods: Using the passive monitoring method, a new survey on indoor radon concentrations was conducted in 2,875 dwellings across 31 provincial capital cities in Chinese mainland from 2018 to 2023. The attributable risk of lung cancer induced by indoor radon exposure was estimated based on the risk assessment model.

Results: The arithmetic mean (AM) and geometric mean (GM) of indoor radon concentrations were 65 Bq/m³ and 55 Bq/m³, respectively, with 13.6% of measured dwellings exceeding 100 Bq/m³ and 0.6% exceeding 300 Bq/m³. The estimated number of lung cancer deaths induced by indoor radon exposure was 150,795, accounting for 20.30% (95% CI: 20.21%-20.49%) of the lung cancer death toll.

Conclusion: This study provided the most recent data on national indoor radon levels in urban areas and the attributable risk of lung cancer. These results served as an important foundation for further research on the disease burden of indoor radon exposure and radon mitigation efforts.

目的:分析中国城市室内氡水平现状,评估氡诱发肺癌的人群风险。方法:采用被动监测方法,对2018 - 2023年中国大陆31个省会城市2875户居民进行室内氡浓度调查。基于风险评估模型估算室内氡暴露诱发肺癌的归因风险。结果:室内氡浓度的算术平均值(AM)和几何平均值(GM)分别为65 Bq/m³和55 Bq/m³,其中13.6%的被测住宅超过100 Bq/m³,0.6%超过300 Bq/m³。室内氡暴露导致的肺癌死亡人数估计为150,795人,占肺癌死亡人数的20.30% (95% CI: 20.21%-20.49%)。结论:本研究提供了全国城市地区室内氡水平和肺癌归因风险的最新数据。这些结果为进一步研究室内氡暴露的疾病负担和减少氡的努力提供了重要基础。
{"title":"Indoor Radon Survey in 31 Provincial Capital Cities and Estimation of Lung Cancer Risk in Urban Areas of China.","authors":"Xiaoxiang Miao, Yinping Su, Changsong Hou, Yanchao Song, Bowei Ding, Hongxing Cui, Yunyun Wu, Quanfu Sun","doi":"10.3967/bes2024.165","DOIUrl":"https://doi.org/10.3967/bes2024.165","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to analyze the current indoor radon level and estimate the population risk of radon-induced lung cancer in urban areas of China.</p><p><strong>Methods: </strong>Using the passive monitoring method, a new survey on indoor radon concentrations was conducted in 2,875 dwellings across 31 provincial capital cities in Chinese mainland from 2018 to 2023. The attributable risk of lung cancer induced by indoor radon exposure was estimated based on the risk assessment model.</p><p><strong>Results: </strong>The arithmetic mean (AM) and geometric mean (GM) of indoor radon concentrations were 65 Bq/m³ and 55 Bq/m³, respectively, with 13.6% of measured dwellings exceeding 100 Bq/m³ and 0.6% exceeding 300 Bq/m³. The estimated number of lung cancer deaths induced by indoor radon exposure was 150,795, accounting for 20.30% (95% <i>CI</i>: 20.21%-20.49%) of the lung cancer death toll.</p><p><strong>Conclusion: </strong>This study provided the most recent data on national indoor radon levels in urban areas and the attributable risk of lung cancer. These results served as an important foundation for further research on the disease burden of indoor radon exposure and radon mitigation efforts.</p>","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1294-1302"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polyunsaturated Fatty Acid Concentrations and Risk of Pneumoconiosis: A Two-sample Mendelian Randomization Study. 多不饱和脂肪酸浓度与尘肺病风险:双样本孟德尔随机研究》。
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.166
Junyi He, Chenwei Zhang, Yukai Zhang, Jingfen Zhang, Xuesen Su, Peiyun He, Wenhui Bao, Haizhao Liu, Xiao Yu, Yiwei Shi
{"title":"Polyunsaturated Fatty Acid Concentrations and Risk of Pneumoconiosis: A Two-sample Mendelian Randomization Study.","authors":"Junyi He, Chenwei Zhang, Yukai Zhang, Jingfen Zhang, Xuesen Su, Peiyun He, Wenhui Bao, Haizhao Liu, Xiao Yu, Yiwei Shi","doi":"10.3967/bes2024.166","DOIUrl":"https://doi.org/10.3967/bes2024.166","url":null,"abstract":"","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1328-1333"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of Mumps Outbreaks in Four Fujian Province Schools. 福建省四所学校流行性腮腺炎暴发特点
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.143
Zhifei Chen, Ruihong Wu, Xiuhui Yang, Yong Zhou, Weiyi Pan, Dong Li
{"title":"Characteristics of Mumps Outbreaks in Four Fujian Province Schools.","authors":"Zhifei Chen, Ruihong Wu, Xiuhui Yang, Yong Zhou, Weiyi Pan, Dong Li","doi":"10.3967/bes2024.143","DOIUrl":"https://doi.org/10.3967/bes2024.143","url":null,"abstract":"","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1324-1327"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to the Acceptance of Tuberculosis Preventive Treatment: A Multicenter Cross-sectional Study in China. 接受结核病预防治疗的障碍:中国多中心横断面研究。
Pub Date : 2024-11-20 DOI: 10.3967/bes2024.150
Jingjuan Ren, Fei Huang, Haifeng Chen, Huimin Zhang, Jianwei Sun, Ahui Zhao, Zuhui Xu, Liqin Liu, Huizhong Wu, Lanjun Fang, Chengguo Wu, Qingya Wang, Wenqian Zhang, Xinhua Sun, Xiaoping Liu, Jizheng Yuan, Bohan Chen, Ni Wang, Yanlin Zhao

Objective: We aimed to understand the willingness and barriers to the acceptance of tuberculosis (TB) preventive treatment (TPT) among people with latent TB infection (LTBI) in China.

Methods: A multicenter cross-sectional study was conducted from May 18, 2023 to December 31, 2023 across 10 counties in China. According to a national technical guide, we included healthcare workers, students, teachers, and others occupations aged 15-65 years as our research participants.

Results: Overall, 17.0% (183/1,077) of participants accepted TPT. There were statistically significant differences in the acceptance rate of TPT among different sexes, ages, educational levels, and occupations ( P < 0.05). The main barriers to TPT acceptance were misconceptions that it had uncertain effects on prevention (57.8%, 517/894), and concerns about side effects (32.7%, 292/894).

Conclusion: An enhanced and comprehensive understanding of LTBI and TPT among people with LTBI is vital to further expand TPT in China. Moreover, targeted policies need to be developed to address barriers faced by different groups of people.

目的:了解中国潜伏性结核感染(LTBI)人群接受结核病预防治疗(TPT)的意愿和障碍。方法:于2023年5月18日至2023年12月31日在中国10个县进行多中心横断面研究。根据国家技术指南,我们纳入了15-65岁的医疗工作者、学生、教师和其他职业作为我们的研究参与者。结果:总体而言,17.0%(183/ 1077)的参与者接受了TPT。不同性别、年龄、文化程度、职业的TPT接受率差异有统计学意义(P < 0.05)。接受TPT的主要障碍是对其预防效果不确定的误解(57.8%,517/894)和对副作用的担忧(32.7%,292/894)。结论:提高和全面了解LTBI患者对LTBI和TPT的认识对于进一步扩大TPT在中国的应用至关重要。此外,需要制定有针对性的政策,以解决不同人群面临的障碍。
{"title":"Barriers to the Acceptance of Tuberculosis Preventive Treatment: A Multicenter Cross-sectional Study in China.","authors":"Jingjuan Ren, Fei Huang, Haifeng Chen, Huimin Zhang, Jianwei Sun, Ahui Zhao, Zuhui Xu, Liqin Liu, Huizhong Wu, Lanjun Fang, Chengguo Wu, Qingya Wang, Wenqian Zhang, Xinhua Sun, Xiaoping Liu, Jizheng Yuan, Bohan Chen, Ni Wang, Yanlin Zhao","doi":"10.3967/bes2024.150","DOIUrl":"10.3967/bes2024.150","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to understand the willingness and barriers to the acceptance of tuberculosis (TB) preventive treatment (TPT) among people with latent TB infection (LTBI) in China.</p><p><strong>Methods: </strong>A multicenter cross-sectional study was conducted from May 18, 2023 to December 31, 2023 across 10 counties in China. According to a national technical guide, we included healthcare workers, students, teachers, and others occupations aged 15-65 years as our research participants.</p><p><strong>Results: </strong>Overall, 17.0% (183/1,077) of participants accepted TPT. There were statistically significant differences in the acceptance rate of TPT among different sexes, ages, educational levels, and occupations ( <i>P</i> < 0.05). The main barriers to TPT acceptance were misconceptions that it had uncertain effects on prevention (57.8%, 517/894), and concerns about side effects (32.7%, 292/894).</p><p><strong>Conclusion: </strong>An enhanced and comprehensive understanding of LTBI and TPT among people with LTBI is vital to further expand TPT in China. Moreover, targeted policies need to be developed to address barriers faced by different groups of people.</p>","PeriodicalId":93903,"journal":{"name":"Biomedical and environmental sciences : BES","volume":"37 11","pages":"1303-1309"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biomedical and environmental sciences : BES
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1